Medicare Enrolled
Dr. Rasmia Ahmed, MD
Hematology & Oncology · Framingham, MA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Ahmed from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Ahmed?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Ahmed
Dr. Rasmia Ahmed is a hematology & oncology specialist in Framingham, MA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Ahmed performed 120,166 Medicare services across 2,841 unique beneficiaries.
Between the years covered by Open Payments, Dr. Ahmed received a total of $2,100 from 32 pharmaceutical and/or device companies across 81 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Ahmed is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 1% volume in MA
$2,100 industry payments
Medicare Practice Summary
Medicare Utilization ↗120,166
Medicare services
Top 1% in MA for hematology & oncology
2,841
Unique beneficiaries
$7
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~6,008 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
73,440 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 22,740 | $18 | $30 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
11,960 | $6 | $29 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
2,071 | $8 | $20 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,806 | $104 | $405 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,588 | $8 | $17 |
| Anti-nausea injection (ondansetron/Zofran) | 1,040 | $0 | $1 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
854 | $0 | $1 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
837 | $12 | $75 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
452 | $14 | $60 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
435 | $1 | $5 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
420 | $75 | $290 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
362 | $10 | $40 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
330 | $59 | $260 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
321 | $2 | $5 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
230 | $67 | $250 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
216 | $7 | $170 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
196 | $118 | $520 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
189 | $30 | $175 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
111 | $12 | $60 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
99 | $1 | $8 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
78 | $1 | $2 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
77 | $102 | $350 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
76 | $26 | $100 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
68 | $139 | $605 |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 43 | $14 | $25 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
43 | $1 | $2 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
26 | $150 | $600 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
25 | $80 | $350 |
| New patient office visit, complex (60-74 min) | 22 | $191 | $720 |
| Bone marrow biopsy and aspiration A procedure to remove a small sample of bone marrow and liquid for laboratory testing. The sample is analyzed to help diagnose various medical conditions. |
11 | $143 | $450 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
62.4% high complexity
32.2% medium
5.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,100
Total received (2018-2024)
Avg $300/year across 7 years
Top 44% in MA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
32
Companies
81
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,955 (93.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$146 (6.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$989
2023
$444
2022
$35
2021
$24
2020
$144
2019
$261
2018
$203
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$100
Celgene Corporation
$94
Janssen Biotech, Inc.
$92
PFIZER INC.
$84
Novartis Pharmaceuticals Corporation
$63
E.R. Squibb & Sons, L.L.C.
$59
GENZYME CORPORATION
$56
GlaxoSmithKline, LLC.
$47
Gilead Sciences, Inc.
$35
BeiGene USA, Inc.
$34
Exelixis Inc.
$32
Merck Sharp & Dohme LLC
$31
ARRAY BIOPHARMA INC
$29
Coherus Biosciences Inc.
$28
Takeda Pharmaceuticals U.S.A., Inc.
$27
Kite Pharma, Inc.
$25
Abbott Laboratories
$25
Karyopharm Therapeutics Inc.
$25
Tempus AI, Inc
$23
ADC Therapeutics America, Inc.
$23
Janssen Pharmaceuticals, Inc
$22
Astellas Pharma US Inc
$18
Lilly USA, LLC
$17
Top 3 companies account for 28.9% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$271
Celgene Corporation
$227
AstraZeneca Pharmaceuticals LP
$189
Janssen Biotech, Inc.
$171
Exelixis Inc.
$152
ADC Therapeutics America, Inc.
$106
PFIZER INC.
$84
Lilly USA, LLC
$73
Gilead Sciences, Inc.
$64
Novartis Pharmaceuticals Corporation
$63
Amgen Inc.
$59
TESARO, Inc.
$58
GENZYME CORPORATION
$56
GlaxoSmithKline, LLC.
$47
CTI BioPharma Corp.
$41
Abbott Laboratories
$37
Janssen Pharmaceuticals, Inc
$35
BeiGene USA, Inc.
$34
Merck Sharp & Dohme LLC
$31
ARRAY BIOPHARMA INC
$29
Coherus Biosciences Inc.
$28
Takeda Pharmaceuticals U.S.A., Inc.
$27
Kite Pharma, Inc.
$25
Daiichi Sankyo Inc.
$25
Karyopharm Therapeutics Inc.
$25
AbbVie, Inc.
$25
Eisai Inc.
$24
Puma Biotechnology, Inc.
$24
Tempus AI, Inc
$23
Astellas Pharma US Inc
$18
Merck Sharp & Dohme Corporation
$15
Genentech USA, Inc.
$13
Top 3 companies account for 32.7% of all-time payments
Associated products mentioned in payments ›
ALIMTA · BRAFTOVI · BRUKINSA · CABOMETYX · Cabometyx · DARZALEX · ELIQUIS · ENHERTU · ENJAYMO · ERLEADA · Enhertu · FREESTYLE LIBRE 3 · FRUZAQLA · FreeStyle Libre · IBRANCE · INREBIC · JEMPERLI · KEYTRUDA · KISQALI · Kyprolis · LYNPARZA · Lenvima · Nerlynx · Neulasta · OJJAARA · OPDIVO · OPDUALAG · Perjeta · Pomalyst · REBLOZYL · RYBREVANT · SCEMBLIX · TAGRISSO · Trodelvy · Udenyca · VERZENIO · Venclexta · Vonjo · XPOVIO · XT CDX · Xtandi · Yescarta · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (93%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
271
Per 100K population
16.7
County median income
$126,779
Nearest hospital
METROWEST MEDICAL CENTER
2.6 mi
2.6 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Ahmed is a mixed practice specialist, with above-average Medicare volume (top 1% in MA), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Ahmed experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Ahmed performed 73,440 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Ahmed receive payments from pharmaceutical companies?
Yes. Dr. Ahmed received a total of $2,100 from 32 companies across 81 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Ahmed's costs compare to other hematology & oncology specialists in Framingham?
Dr. Ahmed's average Medicare payment per service is $7. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Ahmed) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Framingham
Browse hematology & oncology specialists in Framingham ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in MA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in MA
Which MA hematology & oncology specialists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology